Prophylaxis with ketotifen in rats with portal hypertension: Involvement of mast cell and eicosanoids

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 4, 2008, Pages 383-394

  Sánchez Patán, Fernando ^a   Anchuelo, Raquel ^a   Vara, Elena ^a   García, Cruz ^a   Saavedra, Yolanoa ^b   Vergara, Patri ^b   Cuellar, Carmen ^a   Rodero, Marta ^a   Aller, Maria Angeles ^a   Arias, Jaime ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Leukotrienes; Mast cell; Portal hypertension; Prostaglandins

Indexed keywords

KETOTIFEN; LEUKOTRIENE B4; LEUKOTRIENE C4; PROSTACYCLIN; PROSTAGLANDIN E2; PROTEINASE; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFICACY; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; MALE; MAST CELL; MAST CELL DEGRANULATION; MESENTERY LYMPH NODE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PROSTAGLANDIN BLOOD LEVEL; PROSTAGLANDIN RELEASE; RADIOIMMUNOASSAY; RAT; SPLANCHNIC BLOOD FLOW; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL MOVEMENT; CHYMASES; DISEASE MODELS, ANIMAL; EICOSANOIDS; HYPERTENSION, PORTAL; ILEUM; INTESTINAL MUCOSA; KETOTIFEN; LYMPH NODES; MALE; MAST CELLS; PORTAL PRESSURE; RATS; RATS, WISTAR; SPLANCHNIC CIRCULATION;

EID: 49749100382     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005;39:S125-130.
2. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using gamma-labeled microspheres. Am J Physiol 1981;240:G371-375.
3. Munoz J, Albillos A, Pérez-Páramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999;276:G687-693.
4. Abraldes JG, Pasarín M, García-Pagán JC. Animal models of portal hypertension. World J Gastroenterol 2006;12:6577-6584.
5. Aller MA, Nava MP, Cuellar C, Chivato T, Arias JL, Sánchez-Patan F, et al. Evolutive phases of experimental prehepatic portal hypertension. J Gastroenterol Hepatol 2007;22:1127-1133.
6. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol 1985;248:G618-625.
7. Colombato LA, Albillos A, Groszmann RJ. Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats. Hepatology 1992;15:323-328.
8. Braillon A, Lee SS, Girod C, Peignoux-Martinot M, Valla D, Lebrec D. Role of portasystemic shunts in the hyperkinetic circulation of the portal hypertensive rat. J Lab Clin Med 1986;108:543-548.
9. Braillon A, Koshy A, Lee SS, Girod C, Lebrec D. Effect of the development of portosystemic shunts in the maintenance of portal hypertension in rats. Gastroenterol Clin Biol 1988;12: 641-645.
10. García-Pagán JC, Fernández M, Bernadich C, Pizcueta P, Piqué JM, Bosch J, et al. Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. Am J Physiol 1994;267:G984-990.
11. Hou MC, Cahill PA, Zhang S, Wang YN, Hendrickson RJ, Redmond EM, et al. Enhanced cyclooxygenase-1 expression within the superior mesenteric artery of portal hypertensive rats: role in the hyperdynamic circulation. Hepatology 1998;27:20-27.
12. Benoit JN, Womack WA, Hernandez L, Granger DN. "Forward" and "backward" flow mechanisms of portal hypertension. Relative contributions in the rat model of portal vein stenosis. Gastroenterology 1985;89:1092-1096.
13. Aller MA, Arias JL, Lorente L, Nava MP, Durán HJ, Arias J. Neuro-immune-endocrine functional system and vascular pathology. Med Hypotheses 2001;57:561-569.
14. Harrison DG, Widder J, Grumbach I, Chen W, Weber M, Searles C. Endothelial mechanotransduction, nitric oxide and vascular inflammation. J Intern Med 2006;259:351-363.
15. Garcia-Tsao G, Albillos A, Barden GE, West AB. Bacterial translocation in acute and chronic portal hypertension. Hepatology 1993;17:1081-1085.
16. Hashimoto N, Ohyanagi H. Effect of acute portal hypertension on gut mucosa. Hepatogastroenterology 2002; 49:1567-1570.
17. Schimpl G, Pesendorfer P, Steinwender G, Feierl G, Ratschek M, Hollwarth ME. Allopurinol and glutamine attenuate bacterial translocation in chronic portal hypertensive and common bile duct ligated growing rats. Gut 1996;39:48-53.
18. Chiva M, Guarner C, Peralta C, Llovet T, Gómez G, Soriano G, et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2003;15:145-150.
19. Diez-Arias JA, Aller MA, Palma MD, Arias JL, Muniz E, Sánchez M, et al. Increased duodenal mucosa infiltration by mast cells in rats with portal hypertension. Dig Surg 2001; 18:34-40.
20. Prieto I, Aller MA, Santamaria L, Nava MP, Madero R, Pérez-Robledo JP, et al. Prehepatic portal hypertension produces increased mast cell density in the small bowel and in mesenteric lymph nodes in the rat. J Gastroenterol Hepatol 2005;20:1025-1031.
21. Stein J, Ries J, Barrett KE. Disruption of intestinal barrier function associated with experimental colitis: possible role of mast cells. Am J Physiol 1998;274:G203-209.
22. Craps LP, Ney UM. Ketotifen: current views on its mechanism of action and their therapeutic implications. Respiration 1984;45:411-421.
23. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990;40:412-448.
24. Giunchedi P, Conte U. Spray-drying as a preparation method of microparticulate drug delivery systems: an overview. STP Pharm Sci 1995;5:276-283.
25. Boyce JA. Eicosanoid mediators of mast cells: receptors, regulation of synthesis, and pathobiologic implications. Chem Immunol Allergy 2005;87:59-79.
26. Guerrero S, Muníz E, Teijón C, Olmo R, Teijón JM, Blanco MD. Ketotifen-loaded microspheres prepared by spray-drying poly(D,L-lactide) and poly(D,L-lactide-co-glycolide) polymers: Characterization and in vivo evaluation. J Pharm Sci 2007 Nov 19 [Epub ahead of print].
27. Monterde G, Rodríguez-Fabian G, Vara E, López L, Arias J, Aller MA, et al. Increased plasma levels of corticosterone and prolactin and decreased T3 and T4 levels in short-term prehepatic portal hypertension in rats. Dig Dis Sci 2000;45:1865-1871.
28. Huntley JF, Mackellar A, Newlands GF, Irvine J, Miller HR. Mapping of the rat mast cell granule proteinases RMCP I and II by enzyme-linked immunosorbent assay and paired immunofluorescence. APMIS 1990;98:933-944.
29. Serna H, Porras M, Vergara P. Mast cell stabilizer ketotifen [4-(1-methyl-4-piperidylidene)-4h-benzo[4, 5] cyclohepta [1,2-b] thiophen-10(9H)-one fumarate] prevents mucosal mast cell hyperplasia and intestinal dysmotility in experimental Trichinella spiralis inflammation in the rat. J Pharmacol Exp Ther 2006;319:1104-1111.
30. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248-254.
31. Viggiano TR, Gostout CJ. Portal hypertensive intestinal vasculopathy: a review of the clinical, endoscopic, and histopathologic features. Am J Gastroenterol 1992;87:944-954.
32. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002;35:622-629.
33. Chiva M, Soriano G, Rochat I, Peralta C, Rochat F, Llovet T, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002;37:456-462.
34. Schimpl G, Pabst MA, Feierl G, Kuesz A, Ozbey H, Takahashi S, et al. A tungsten supplemented diet attenuates bacterial translocation in chronic portal hypertensive and cholestatic rats: role of xanthine dehydrogenase and xanthine oxidase. Gut 1999;45:904-910.
35. Fernando B, Marley R, Holt S, Anand R, Harry D, Sanderson P, et al. N-acetylcysteine prevents development of the hyperdynamic circulation in the portal hypertensive rat. Hepatology 1998;28:689-694.
36. Cahill PA, Redmond EM, Sitzmann JV. Endothelial dysfunction in cirrhosis and portal hypertension. Pharmacol Ther 2001;89:273-293.
37. Wiest R, Shah V, Sessa WC, Groszmann RJ. NO overproduction by eNOS precedes hyperdynamic splanchnic circulation in portal hypertensive rats. Am J Physiol 1999;276:G1043-1051.
38. Bruckdorfer R. The basics about nitric oxide. Mol Aspects Med 2005;26:3-31.
39. Vliagoftis H, Befus AD. Mast cells at mucosal frontiers. Curr Mol Med 2005;5:573-589.
40. Lützelschwab C, Pejler G, Aveskogh M, Hellman L. Secretory granule proteases in rat mast cells. Cloning of 10 different serine proteases and a carboxypeptidase A from various rat mast cell populations. J Exp Med 1997;185:13-29.
41. Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. Annu Rev Immunol 2005;23:749-786.
42. Lundequist A, Tchougounova E, Abrink M, Pejler G. Cooperation between mast cell carboxypeptidase A and the chymase mouse mast cell protease 4 in the formation and degradation of angiotensin II. J Biol Chem 2004;279:32339-32344.
43. Touyz RM. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005;14:125-131.
44. Yedgar S, Cohen Y, Shoseyov D. Control of phospholipase A2 activities for the treatment of inflammatory conditions. Biochim Biophys Acta 2006;1761:1373-1382.
45. Morteau O. Prostaglandins and inflammation: the cyclooxygenase controversy. Arch Immunol Ther Exp (Warsz) 2000;48:473-480.
46. Okayama Y, Kawakami T. Development, migration and survival of mast cells. Immunol Res 2006;34:97-115.
47. Wang HW, Tedla N, Lloyd AR, Wakefield D, McNeil PH. Mast cell activation and migration to lymph nodes during induction of an immune response in mice. J Clin Invest 1998;102:1617-1626.
48. Zardi EM, Zardi DM, Dobrina A, Afeltra A. Prostacyclin in sepsis: a systematic review. Prostaglandins Other Lipid Mediat 2007;83:1-24.
49. Nakano T, Ohara O, Teraoka H, Arita H. Glucocorticoids suppress group II phospholipase A2 production by blocking mRNA synthesis and post-transcriptional expression. J Biol Chem 1990;265:12745-12748.
50. Hu KQ. Cyclooxygenase 2 (COX-2)-prostanoid pathway and liver diseases. Prostaglandins Leukot Essent Fatty Acids 2003;69:329-337.
51. Clària J, Romano M. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharm Des 2005;11:3431-3447.
52. Sitzmann JV, Campbell K, Wu Y, St Clair C. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery 1994;115:290-294.
53. Wu ZY, Chen XS, Qiu JF, Cao H. Role of PGI2 in the formation and maintenance of hyperdynamic circulatory state of portal hypertensive rats. World J Gastroenterol 2005;11:752-755.
54. Cao H, Xu J, Hua R, Meng FB, Qiu JF, Wu ZY. Expression of cyclooxygenase in hyperdynamic portal hypertensive rats. Hepatobiliary Pancreat Dis Int 2006;5:252-256.
55. Cao H, Xu J, Liu H, Meng FB, Qiu JF, Wu ZY. Influence of nitric oxide synthase and cyclooxygenase blockade on expression of cyclooxygenase and hemodynamics in rats with portal hypertension. Hepatobiliary Pancreat Dis Int 2006;5:564-569.
56. Granger DN, Richardson PD, Taylor AE. Volumetric assessment of the capillary filtration coefficient in the cat small intestine. Pflugers Arch 1979;381:25-33.
57. Neumann UP, Kaisers U, Langrehr JM, Glanemann M, Müller AR, Lang M, et al. Reduction of reperfusion injury with prostacyclin I2 after liver transplantation. Transplant Proc 1999;31:1029-1030.
58. Wallace JL. Prostaglandin biology in inflammatory bowel disease. Gastroenterol Clin North Am 2001;30:971-980.
59. Calder PC, Grimble RF. Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 2002;56:S14-19.
60. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2003; 4:974-981.
61. Malaviya R, Abraham SN. Role of mast cell leukotrienes in neutrophil recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol 2000;67:841-846.
62. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol 2003;4:965-973.
63. Ogawa Y, Calhoun WJ. The role of leukotrienes in airway inflammation. J Allergy Clin Immunol 2006;118:789-800.
64. Tkaczyk C, Villa I, Peronet R, David B, Mécheri S. FcepsilonRI-mediated antigen endocytosis turns interferon-gamma-treated mouse mast cells from inefficient into potent antigen-presenting cells. Immunology 1999;97:333-340.
65. Vega De Céniga M, Valdés F, Aller MA, Nava MP, Chivato T, et al. Budesonide ameliorates early portal hypertension in the rat: possible antiexudative splanchnic action. Inflammopharmacology 2003; 11:211-222.
66. Carrà S, Gagliardi L, Zanconato S, Scollo M, Azzolin N, Zacchello F, et al. Budesonide but not nedocromil sodium reduces exhaled nitric oxide levels in asthmatic children. Respir Med 2001;95:734-739.
67. Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu Rev Med 2001;52: 299-318.
68. Shiratori Y, Tanaka M, Umihara J, Kawase T, Shiina S, Sugimoto T. Leukotriene inhibitors modulate hepatic injury induced by lipopolysaccharide-activated macrophages. J Hepatol 1990;10:51-61.
69. Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, Salas A, et al. Modulatory effect of nitric oxide on mast cells during induction of dextran sulfate sodium colitis. Dig Dis Sci 2007;52:45-51.
70. Lin HC, Soubrane O, Lebrec D. Prevention of portal hypertension and portosystemic shunts by early chronic administration of clonidine in conscious portal vein-stenosed rats. Hepatology 1991;14:325-330.
71. Maurer M, Theoharides T, Granstein RD, Bischoff SC, Bienenstock J, Henz B, et al. What is the physiological function of mast cells? Exp Dermatol 2003;12:886-910.
72. Gregory GD, Brown MA. Mast cells in allergy and autoimmunity: implications for adaptive immunity. Methods Mol Biol 2006;315:35-50.